|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Baseline symptoms of depression and anxiety negatively impact the effectiveness of CBTi in treating acute insomnia among young adults显示文摘Background Cognitive-behavioural therapy for insomnia(CBTi)is the first-line treatment for those with this sleep disorder.However,depressive and anxiety symptoms often co-occur with acute insomnia,which may affect the effectiveness of CBTitreatment.Aims This study aimed to determine the impact of depressive and anxiety symptoms on the efficacy of CBTi in treating acute insomnia.Methods A single-arm clinical trial was conducted among individuals who have acute insomnia.Participants underwent self-guided CBTi for 1-week.Their insomnia,depressive symptoms and anxiety symptoms were evaluated using the Insomnia Severity Index and the Hospital Anxiety and Depression Scale at baseline,post-treatment and 3-month follow-up.Repeated measures analysis of variance was used to assess the effectiveness of CBTi in treating insomnia,depressive symptoms and anxiety symptoms.A multivariate Cox regression model was used to determine the impact of depressive and anxiety symptoms on insomnia.Results The study found significant reductions in insomnia,depressive symptoms and anxiety symptoms at both post-treatment and 3-month follow-up(F=17.45,p<0.001;F=36.37,p=0.001;and F=81.51,p<0.001,respectively).The duration of CBTi treatment had a positive impact on insomnia recovery(hazard ratio(HR)=0.94,p=0.018).However,baseline depressive symptoms(HR=1.83,p=0.004)and baseline anxiety symptoms(HR=1.99,p=0.001)had significant negative effects on insomnia recovery.Conclusions The study showed that a 1-week self-guided CBTi treatment is effective in treating acute insomnia and comorbid depressive and anxiety symptoms.However,baseline depressive and anxiety symptoms negatively impact treatment effectiveness.Therefore,clinicians should assess for depressive and anxiety symptoms before treating acute insomnia with monotherapy CBTi. | Chenxi Zhang Shufei Zeng Yan Xu Shuai Liu Shixu Du Leqin Fang Zhihong Lv Lili Zhang Bin Zhang | 2023 | General Psychiatry2023，36，3： | 1 |
| 2 | Correlation between Vascular Calcification and Serum Sclerostin in MHD Patients显示文摘Objective Investigate the correlation between serum sclerostinlevel and chronic kidney disease-mineral and bone disorder(CKD-MBD),especially vascular calcification,in maintenance hemodialysis(MHD)patients.Methods This is across-sectional study,a total of 72 MHD patients were included from the first affiliated hospital of Jinan university.Measure the biochemical indicators of mineral metabolism,renal function,and serum sclerostin level by ELISA.The abdominal aorta calcification score(AACS)was assessed according to Kauppila method on lateral spine imaging using DEXA.Patients were distributed into two groups according to the level of serum sclerostin:low sclerostingroup(≤125 pg/ml)and high sclerostingroup(>125 pg/ml).Analyze the association of serum sclerostin level with the indicators of CKD-MBD.Results There was significant difference in i PTH level between high sclerost in group and low sclerost in group.Multivariate Logistic regression analysis demonstrated that dialysis duration,male and anuria were independent risk factor of high sclerostin level,and i PTH and Kt/V were protective factors.Conclusion Dialysis duration,man,anuria was independent risk factors and i PTH,Kt/V were protective factors of high serum sclerostin level in MHD patients.There was no correlation between abdominal aorta calcification and serum sclerostin level. | Yangyang Zhang Shufei Zeng Chen Yun Lifeng Yang Fanna Liu Guanmin Wu Taksui Wong Bo Hu Xiangnan Dong Folan Li Yu Chen Peitian Yang Aiyun Cha Huanhuan Liu Mingming Ma B.Hocher W. Pommer Huiyuan Zheng Tong Liu Zuhui Chen Lianghong Yin | 2017 | 临床医学工程2017，24，S1： | 0 |
| 3 | Advances in Diagnosis and Treatment of Neuropsychiatric Systemic Lupus Erythematosus显示文摘1 Introduction Neuropsychiatric systemic lupus erythematosus(NPSLE)is a serious complication of systemic lupus erythematosus(SLE),with an incidence of about 30%to 40%[1].No matter early or late SLE patients are prone to concurrent,so early diagnosis and treatment of NPSLE is extremely important. | Shufei Zeng Yangyang Zang Dezhen Chen Baozhang Guan Fanna Liu Mingming Ma Yu Mong Huiyuan Zheng Aiyun Cha Xiangnan Dong Huanhuan Liu Taksui Wong Shuang Cui Tong Liu Yongpin Lu Chen Yun Hongwei Hu B.Hocher W.Pommer Zuhui Chen Lianghong Yin | 2017 | 临床医学工程2017，24，S1： | 0 |
| 4 | Peritoneal Dialysis: Prospects and Challenges显示文摘There are 3 kinds of Renal Replacement Therapy:hemodialysis,peritoneal dialysis and kidney transplantation.Although a kidney transplant would be the best solution,organ donations are limited and the transplanted organs can be rejected by the body.Hemodialysis is a widely recognized and near-universally available treatment method,however,the patient must make at least 3 weekly visits to a hospital to undergo treatment,with each session lasting on average around 4 hours.Consequently this can have an impact on the patients’life,including work and travel.Since the clinical populariza- | Lifeng Yang Jun Ke Jie Huang Hongwei Hu Shaofeng Huang Jie Shu Bo Hu Aiyun Cha Xiangnan Dong Guanmin Wu Fanna Liu Yu Chen Huanhuan Liu Mingming Ma Taksui Wong Lianghong Yin Chen Yun Shufei Zeng Baozhang Guan Zuhui Chen | 2017 | 临床医学工程2017，24，S1： | 0 |
| 5 | The Research Progression of Calcitonin for the Therapy of Renal Osteodystrophy显示文摘Calcitonin is a common medicine used in the treatment of osteoporosis,which could restrain the activity of osteoclasts,stop the loss of osteocalcin and reduce the transfer of osteocalcin.Calcitonin can also be used in the treatment of the pain-caused diseases which usually cause by hypercalcemia and others such like Paget's disease and bone tumors.As is approved by several clinic researches,calcitonin is powerful in adjusting the level of calcium,phosphorus and PTH during the treatment of renal osteodystrophy.In addition,it could improves the life quality of the patients who suffered from chronic kidney disease(CKD)and extending their life period.At present,several studies have shown us Calcitonin could be treated in renal osteodystrophy.However,the treatment experiences of Calcitonin are still lacking.Better understanding of the clinical evaluation for calcitonin in the treatment of renal osteodystrophy will hopefully help us to improve outcomes for these patients. | Yingyan LI Sibo HUANG Shengling HUANG Shuang CUI Xiangnan DONG Yueling ZHU Baozhang GUAN Taksui WONG Bing YAN Bo HU Xin CHEN Shanshan LI Fanna LIU Huiyuan ZHENG Tong LIU Hongwei HU Shaofeng HUANG Shufei ZENG Chen YUN Wolfgang Pommer Zuhui CHEN Lianghong YIN Berthold Hocher | 2017 | 临床医学工程2017，24，S1： | 0 |
| 6 | The Pathogenesis of the Mechanism of FGF23 in Chronic Kidney Disease Patients with Vascular Calcification显示文摘Fibroblast growth factor 23(FGF23)is a protein synthesized by bone cell and the osteoblast with endocrine function.The main role of FGF23 is to regulate serum phosphorus and 1,25(OH)2 D3 levels,it also plays an important role in calcium and phosphorus metabolism.The role of FGF23 in renal disease is to inhibit of phosphorus reabsorption,promote urinary phosphorus excretion and maintain a stable blood phosphorus level.Patients with chronic kidney disease(CKD)have more risk to suffer cardiovascular disease(CVD)which is related to the abnormal metabolism of calcium and phosphorus.FGF23,as newly discovered cardiovascular risk marker,several studies have shown that FGF23 level associates with multiple cardiovascular risk factors in CKD patients,especially in CKD patients with vascular calcification.To explore its pathogenesis of vascular calcification in CKD patients is particularly important,and that may help to take appropriate measures to improve the prognosis of CKD patients. | Shanshan LI Wenyu GNOG Sibo HUANG Lianghong YIN Bo HU Xiangnan DONG Taksui WONG Fanna LIU Yingyan LI Yueling ZHU Xin CHEN Baozhang GUAN Shengling HUANG Shuang CUI Bing YAN Hongwei HU Shaofeng HUANG Yongpin LU Shufei ZENG Chen YUN Berthold Hocher Wolfgang Pomme | 2017 | 临床医学工程2017，24，S1： | 0 |
| 7 | Treatment of Sepsis by Hemofiltration Combined with Plasma Exchange in One Case显示文摘Female patients,44 years old,due to'regular peritoneal dialysis5 years,stomach ache 1 week'admission.Previous had 2 times for'Peritoneal dialysis related peritonitis'in hospital,after anti-infection treatment patients symptoms improved and discharged.1 week ago in patients admitted to hospital because of abdominal pain again.Physical:abdominal tenderness,bowel sounds hyperthyroidism.Laboratory inspection index:CRP:172.22 mg/l,WBC:23.26×10~9/L,NEU%:89.23%,D dimer:3 800 ng/ml,PCT:14.86 ng/ml。 | Weilong Li Sibo Huang Shuang Cui Zongchao Yu Shufei Zeng Bo Hu Aiyun Cha Jian Li Huixia Yu Mingming Ma Xiangnan Dong Xiaoyi Chen W.Pommer Chen Yun Lianghong Yin | 2017 | 临床医学工程2017，24，S1： | 0 |
| 8 | Efficacy and Safety of Febuxost at in the Treatment of Chronic Kidney Disease with Hyperuricemia: A Meta- Analysis显示文摘Background Febuxostat and allopurinol have different pharmacological mechanisms,the efficacy of febuxostat in chronic kidney disease complicated with hyperuricemia remains controversial.A meta-analysis and systemic review was conducted to investigate the efficacy and safety of febuxostat in CKD populations complicated with hyperuricemia.Methods A comprehensive search was conducted in multiple electronic databases based on the inclusion and exclusion criteria,before December 2016,searching for the published studies,including Chinese and English,relating to the use of febuxostat in CKD populations complicated with hyperuricemia,and manual retrieval of the inclusion literature.Literature evaluation and data extraction were performed by two reviewers,Rev Man 5.3 was used to perform the meta-analysis.Results Seven studies with 482 CKD patients were included in the meta-analysis.We found that febuxostat can significantly slow the decreasing speed of e GFR[RR=4.90,95%CI(1.95,7.84),P=0.001],and reduce serum uric acid[RR=-99.30,95%CI(-172.24,-26.37),P=0.008]levels in CKD patients complicated with hyperuricemia when compairing with control group.There was no significant difference in the levels of systolic blood pressure[RR=-2.19,95%CI(-9.99,5.61),P=0.58],diastolic blood pressure[RR=-2.30,95%CI(-7.33,2.73),P=0.10],low density lipoprotein[RR=-0.47,95%CI(-7.64,6.69),P=0.90]between the two groups.Compared with the control group,the use of febuxostat increase the incidence of adverse reaction[RR=4.73,95%CI(1.04,21.43),P=0.04]in patients.Conclusions Febuxostat can significantly lower serum uric acid level and effectively delay the process of chronic renal failure in CKD patients complicated with hyperuricemic,increases the incidence of adverse reaction,no significant difference in SBP,DBP,LDL,when compared with control group. | Jingyun Ou Bin Yan Shenling Huang Mingming Ma Jun Ke Hongwei Hu Sibo Huang Xiangnan Dong Aiyun Cha Zuhui Chen Yu Mong Fanna Liu W.Pommer Chen Yun Yongpin Lu Shufei Zeng Lianghong Yin B.Hocher | 2017 | 临床医学工程2017，24，S1： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员